Esophageal and esophagogastric junction cancers, Version 1.2015

Jaffer A. Ajani; Thomas A. D'Amico; Khaldoun Almhanna; David J. Bentrem; Stephen Besh; Joseph Chao; Prajnan Das; Crystal Denlinger; Paul Fanta; Charles S. Fuchs; Hans Gerdes; Robert E. Glasgow; James A. Hayman; Steven Hochwald; Wayne L. Hofstetter; David H. Ilson; Dawn Jaroszewski; Kory Jasperson; Rajesh N. Keswani; Lawrence R. Kleinberg; W. Michael Korn; Stephen Leong; A. Craig Lockhart; Mary F. Mulcahy; Mark B. Orringer; James A. Posey; George A. Poultsides; Aaron R. Sasson; Walter J. Scott; Vivian E. Strong; Thomas K. Varghese; Mary Kay Washington; Christopher G. Willett; Cameron D. Wright; Debra Zelman; Nicole McMillian; Hema Sundar

doi:10.6004/jnccn.2015.0028

Esophageal and esophagogastric junction cancers, Version 1.2015

Jaffer A. Ajani, Thomas A. D'Amico, Khaldoun Almhanna, David J. Bentrem, Stephen Besh, Joseph Chao, Prajnan Das, Crystal Denlinger, Paul Fanta, Charles S. Fuchs, Hans Gerdes, Robert E. Glasgow, James A. Hayman, Steven Hochwald, Wayne L. Hofstetter, David H. Ilson, Dawn Jaroszewski, Kory Jasperson, Rajesh N. Keswani, Lawrence R. KleinbergW. Michael Korn, Stephen Leong, A. Craig Lockhart, Mary F. Mulcahy, Mark B. Orringer, James A. Posey, George A. Poultsides, Aaron R. Sasson, Walter J. Scott, Vivian E. Strong, Thomas K. Varghese, Mary Kay Washington, Christopher G. Willett, Cameron D. Wright, Debra Zelman, Nicole McMillian, Hema Sundar

Cardiovascular & Thoracic Surgery

Research output: Contribution to journal › Review article › peer-review

248 Scopus citations

Abstract

Esophageal cancer is the sixth most common cause of cancer deaths worldwide. Adenocarcinoma is more common in North America and Western European countries, originating mostly in the lower third of the esophagus, which often involves the esophagogastric junction (EGJ). Recent randomized trials have shown that the addition of preoperative chemoradiation or perioperative chemotherapy to surgery significantly improves survival in patients with resectable cancer. Targeted therapies with trastuzumab and ramucirumab have produced encouraging results in the treatment of advanced or metastatic EGJ adenocarcinomas. Multidisciplinary team management is essential for patients with esophageal and EGJ cancers. This portion of the NCCN Guidelines for Esophageal and EGJ Cancers discusses management of locally advanced adenocarcinoma of the esophagus and EGJ.

Original language	English (US)
Pages (from-to)	194-227
Number of pages	34
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	13
Issue number	2
DOIs	https://doi.org/10.6004/jnccn.2015.0028
State	Published - Feb 1 2015

ASJC Scopus subject areas

Oncology

Access to Document

10.6004/jnccn.2015.0028

Cite this

Ajani, J. A., D'Amico, T. A., Almhanna, K., Bentrem, D. J., Besh, S., Chao, J., Das, P., Denlinger, C., Fanta, P., Fuchs, C. S., Gerdes, H., Glasgow, R. E., Hayman, J. A., Hochwald, S., Hofstetter, W. L., Ilson, D. H., Jaroszewski, D., Jasperson, K., Keswani, R. N., ... Sundar, H. (2015). Esophageal and esophagogastric junction cancers, Version 1.2015. JNCCN Journal of the National Comprehensive Cancer Network, 13(2), 194-227. https://doi.org/10.6004/jnccn.2015.0028

Ajani, JA, D'Amico, TA, Almhanna, K, Bentrem, DJ, Besh, S, Chao, J, Das, P, Denlinger, C, Fanta, P, Fuchs, CS, Gerdes, H, Glasgow, RE, Hayman, JA, Hochwald, S, Hofstetter, WL, Ilson, DH, Jaroszewski, D, Jasperson, K, Keswani, RN, Kleinberg, LR, Korn, WM, Leong, S, Lockhart, AC, Mulcahy, MF, Orringer, MB, Posey, JA, Poultsides, GA, Sasson, AR, Scott, WJ, Strong, VE, Varghese, TK, Washington, MK, Willett, CG, Wright, CD, Zelman, D, McMillian, N & Sundar, H 2015, 'Esophageal and esophagogastric junction cancers, Version 1.2015', JNCCN Journal of the National Comprehensive Cancer Network, vol. 13, no. 2, pp. 194-227. https://doi.org/10.6004/jnccn.2015.0028

@article{32efa6992f08434da8dd28d91b4439c5,

title = "Esophageal and esophagogastric junction cancers, Version 1.2015",

abstract = "Esophageal cancer is the sixth most common cause of cancer deaths worldwide. Adenocarcinoma is more common in North America and Western European countries, originating mostly in the lower third of the esophagus, which often involves the esophagogastric junction (EGJ). Recent randomized trials have shown that the addition of preoperative chemoradiation or perioperative chemotherapy to surgery significantly improves survival in patients with resectable cancer. Targeted therapies with trastuzumab and ramucirumab have produced encouraging results in the treatment of advanced or metastatic EGJ adenocarcinomas. Multidisciplinary team management is essential for patients with esophageal and EGJ cancers. This portion of the NCCN Guidelines for Esophageal and EGJ Cancers discusses management of locally advanced adenocarcinoma of the esophagus and EGJ.",

author = "Ajani, {Jaffer A.} and D'Amico, {Thomas A.} and Khaldoun Almhanna and Bentrem, {David J.} and Stephen Besh and Joseph Chao and Prajnan Das and Crystal Denlinger and Paul Fanta and Fuchs, {Charles S.} and Hans Gerdes and Glasgow, {Robert E.} and Hayman, {James A.} and Steven Hochwald and Hofstetter, {Wayne L.} and Ilson, {David H.} and Dawn Jaroszewski and Kory Jasperson and Keswani, {Rajesh N.} and Kleinberg, {Lawrence R.} and Korn, {W. Michael} and Stephen Leong and Lockhart, {A. Craig} and Mulcahy, {Mary F.} and Orringer, {Mark B.} and Posey, {James A.} and Poultsides, {George A.} and Sasson, {Aaron R.} and Scott, {Walter J.} and Strong, {Vivian E.} and Varghese, {Thomas K.} and Washington, {Mary Kay} and Willett, {Christopher G.} and Wright, {Cameron D.} and Debra Zelman and Nicole McMillian and Hema Sundar",

note = "Publisher Copyright: {\textcopyright} National Comprehensive Cancer Network, Inc.",

year = "2015",

month = feb,

day = "1",

doi = "10.6004/jnccn.2015.0028",

language = "English (US)",

volume = "13",

pages = "194--227",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

publisher = "Cold Spring Publishing LLC",

number = "2",

}

TY - JOUR

T1 - Esophageal and esophagogastric junction cancers, Version 1.2015

AU - Ajani, Jaffer A.

AU - D'Amico, Thomas A.

AU - Almhanna, Khaldoun

AU - Bentrem, David J.

AU - Besh, Stephen

AU - Chao, Joseph

AU - Das, Prajnan

AU - Denlinger, Crystal

AU - Fanta, Paul

AU - Fuchs, Charles S.

AU - Gerdes, Hans

AU - Glasgow, Robert E.

AU - Hayman, James A.

AU - Hochwald, Steven

AU - Hofstetter, Wayne L.

AU - Ilson, David H.

AU - Jaroszewski, Dawn

AU - Jasperson, Kory

AU - Keswani, Rajesh N.

AU - Kleinberg, Lawrence R.

AU - Korn, W. Michael

AU - Leong, Stephen

AU - Lockhart, A. Craig

AU - Mulcahy, Mary F.

AU - Orringer, Mark B.

AU - Posey, James A.

AU - Poultsides, George A.

AU - Sasson, Aaron R.

AU - Scott, Walter J.

AU - Strong, Vivian E.

AU - Varghese, Thomas K.

AU - Washington, Mary Kay

AU - Willett, Christopher G.

AU - Wright, Cameron D.

AU - Zelman, Debra

AU - McMillian, Nicole

AU - Sundar, Hema

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Esophageal cancer is the sixth most common cause of cancer deaths worldwide. Adenocarcinoma is more common in North America and Western European countries, originating mostly in the lower third of the esophagus, which often involves the esophagogastric junction (EGJ). Recent randomized trials have shown that the addition of preoperative chemoradiation or perioperative chemotherapy to surgery significantly improves survival in patients with resectable cancer. Targeted therapies with trastuzumab and ramucirumab have produced encouraging results in the treatment of advanced or metastatic EGJ adenocarcinomas. Multidisciplinary team management is essential for patients with esophageal and EGJ cancers. This portion of the NCCN Guidelines for Esophageal and EGJ Cancers discusses management of locally advanced adenocarcinoma of the esophagus and EGJ.

AB - Esophageal cancer is the sixth most common cause of cancer deaths worldwide. Adenocarcinoma is more common in North America and Western European countries, originating mostly in the lower third of the esophagus, which often involves the esophagogastric junction (EGJ). Recent randomized trials have shown that the addition of preoperative chemoradiation or perioperative chemotherapy to surgery significantly improves survival in patients with resectable cancer. Targeted therapies with trastuzumab and ramucirumab have produced encouraging results in the treatment of advanced or metastatic EGJ adenocarcinomas. Multidisciplinary team management is essential for patients with esophageal and EGJ cancers. This portion of the NCCN Guidelines for Esophageal and EGJ Cancers discusses management of locally advanced adenocarcinoma of the esophagus and EGJ.

UR - http://www.scopus.com/inward/record.url?scp=84923460712&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923460712&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2015.0028

DO - 10.6004/jnccn.2015.0028

M3 - Review article

C2 - 25691612

AN - SCOPUS:84923460712

VL - 13

SP - 194

EP - 227

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

SN - 1540-1405

IS - 2

ER -

Esophageal and esophagogastric junction cancers, Version 1.2015

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this